Aura Biosciences names new CMO/President of R&D and CTO; CMO Rich transitions to advisor

Aura Biosciences, Inc.

J. Jill Hopkins appointed CMO and President of R&D, effective Oct 16, 2023; prior roles at Novartis, Gyroscope, Roche-Genentech.
Mark Plavsic appointed CTO; 30 years experience including Fate Therapeutics, Sanofi Genzyme, AstraZeneca.
Cadmus Rich resigns as CMO effective Oct 16; will serve as Senior Clinical Advisor through Nov 7, then consultant for 9 months.
Hopkins receives annual base salary of $525k, sign-on bonus up to $200k, and equity grants of 200k options and 135k RSUs.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

J. Jill Hopkins

Chief Medical Officer and President of Research & Development

AURA · Aura Biosciences, Inc.

Effective: 2023-10-16
Filed: October 2, 2023, 7:59 PM ET

J. Jill Hopkins, M.D., will serve as the Company’s Chief Medical Officer and President of Research & Development, effective as of October 16, 2023

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

J. Jill Hopkins was appointed as Chief Medical Officer and President of Research & Development at Aura Biosciences, Inc..

Action: appointed
Role: Chief Medical Officer and President of Research & Development

Exact text from the filing

J. Jill Hopkins, M.D., will serve as the Company’s Chief Medical Officer and President of Research & Development, effective as of October 16, 2023

View on SEC.gov

Aura Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-249055

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.